Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer
Jeff F Hiken, James I McDonald, Keith F Decker, Cesar Sanchez, Jeremy Hoog, Nathan D VanderKraats, Kyle L Jung, Margaret Akinhanmi, Matthew J Ellis, John R Edwards
The paper identifies epigenetic activation of PTGER4 as a mechanism promoting resistance to aromatase inhibitors in breast cancer and suggests it as a potential therapeutic target.
bioRxiv · Jun 2, 2016Cancer Biology